参考文献：
［1］陈良安.规范中国晚期非小细胞肺癌抗血管生成治疗：晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识（2016年版）解读［J］.中华结核和呼吸杂志，2016，39（11）：835-836.DOI：10.3760/cma.j.issn.1001-0939.2016.11.002.
［2］Zheng，Wenjuan，Feng，Jifeng，Song，Xiangqun，et al.BEYOND：A Randomized，Double-Blind，Placebo-Controlled，Multicenter，Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer［J］.Journal of Clinical Oncology，2015，33（19）：2197-2204.
［3］Heist，Rebecca S.，Duda，Dan G.，Sahani，Dushyant V.，et al.Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer［J］.Proceedings of the National Academy of Sciences of the United States of America，2015，112（5）：1547-1552.
［4］Lynch，T.J.，Spigel，D.R.，Brahmer，J.，et al.Safety and effectiveness of bevacizumab-contain ing treatment for nonsmall-cell lung cancer：Final results of the ARIES observational cohort study［J］.Journal of thoracic oncology：official publication of the International Association for the Study of Lung Cancer，2014，9（9）：1332-1339.
［5］de Castro J，Griesinger F，Grossi F，et al.Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy：treatment rationale and protocol dynamics of the AvaALL（MO22097）trial.［J］.Clinical lung cancer，2011，12（6）：407-411.
［6］Du，N.，Fu，Y.，Ma，J.，et al.Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion［J］.Oncology reports，2013，29（6）：2332-2340.
［7］Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2018，68（6）：394-424.(https://www.daowen.com)
［8］Chen W，Sun K，Zheng R，et al.Cancer incidence and mortality in China，2014［J］.Chin J Cancer Res，2018，30（1）：1-12.
［9］Han B，Zhou C.Efficacy and safety of sintilimab with anlotinib as first-line therapy for advanced non-small cell lung cancer［R］.WCLC，2019-04-02.
［10］Han B，Li K，Zhao Y，et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer：a multicentre，randomised phaseⅡtrial（ALTER0302）［J］.Br J Cancer，2018，118（5）：654-661.
［11］Han B，Li K，Wang Q，et al.Effect of anlotinib as a thirdline or further treatment on overall survival of patients with advanced non-small cell lung cancer：the alter 0303 phase 3randomized clinical trial［J］.JAMA oncol，2018，4（11）：1569-1575.
［12］Wu D，Nie J，Dai L，et al.Salvage treatment with anlotinib for advanced non-small cell lung cancer［J］.Thorac Cancer，2019，10（7）：1590-1596.
［13］Najjar F，Alammar M，Al-Massarani G，et al.Circulating endothelial cells and microparticles as diagnostic and prognostic biomarkers in small-cell lung cancer［J］.Lung Cancer，2018，124（12）：23-30.
［14］Si X，Zhang L，Wang H，et al.Quality of life results from a randomized，double-blinded，placebo-controlled，multicenter phaseⅢtrial of anlotinib in patients with advanced nonsmall cell lung cancer［J］.Lung Cancer，2018，122（3）：32-37.